Cornelia Mauch
Expertise in
4
conditions

Cornelia Mauch

Kerpener Str. 62, 
Koeln, NW, DE 
Expertise in
4
conditions
Kerpener Str. 62, 
Koeln, NW, DE 

Overview

Cornelia Mauch practices practicing medicine in Koeln, Germany.

Ms. Mauch is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Melanoma, Metastatic Uveal Melanoma, Merkel Cell Carcinoma, and Uveal Melanoma.

She is actively involved in clinical research, co-authoring 132 peer reviewed articles and participating in 4 clinical trials.

Gender

Female

Locations

Kerpener Str. 62, Koeln, NW 50937, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Enrollment Status: Completed
Publish Date: March 17, 2026
Intervention Type: Biological, Drug
Study Drugs: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
Study Phase: Phase 2
A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Enrollment Status: Completed
Publish Date: April 09, 2025
Intervention Type: Drug
Study Drugs: Vemurafenib, Cobimetinib, Atezolizumab
Study Phase: Phase 2
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drugs: Ipilimumab, IMO-2125
Study Phase: Phase 3
Adjuvant Pegylated-Interferon-alpha2b (SylatronTM) for 2 Years Versus Observation in Patients With an Ulcerated Primary Cutaneous Melanoma With T(2-4)bN0M0: a Randomized Phase III Trial of the EORTC Melanoma Group.
Adjuvant Pegylated-Interferon-alpha2b (SylatronTM) for 2 Years Versus Observation in Patients With an Ulcerated Primary Cutaneous Melanoma With T(2-4)bN0M0: a Randomized Phase III Trial of the EORTC Melanoma Group.
Enrollment Status: Unknown
Publish Date: March 04, 2019
Intervention Type: Biological
Study Drug: PEG IFN Alfa-2b
Study Phase: Phase 3
View 3 Less Clinical Trials

132 Total Publications

Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.
Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.
Journal: Future oncology (London, England)
Published: March 31, 2026

Frequently Asked Questions about Cornelia Mauch

Is Cornelia Mauch a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Cornelia Mauch is classified as an Distinguished expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Cornelia Mauch participate in research or clinical trials?

Yes. Cornelia Mauch has published 132 articles and abstracts on conditions like Melanoma. You can view a list of Cornelia Mauch's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Mauch's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile